Cargando…

Predictors of psychiatric hospitalization during 6 months of maintenance treatment with olanzapine long-acting injection: post hoc analysis of a randomized, double-blind study

BACKGROUND: Hospitalization is a costly and distressing event associated with relapse during schizophrenia treatment. No information is available on the predictors of psychiatric hospitalization during maintenance treatment with olanzapine long-acting injection (olanzapine-LAI) or how the risk of ho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ascher-Svanum, Haya, Novick, Diego, Haro, Josep Maria, Bertsch, Jordan, McDonnell, David, Detke, Holland
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3848477/ https://www.ncbi.nlm.nih.gov/pubmed/24041270 http://dx.doi.org/10.1186/1471-244X-13-224

Ejemplares similares

Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection
por: Ascher-Svanum, Haya, et al.
Publicado: (2014)

Schizophrenia Outpatient Health Outcomes study: twelve-month findings
por: Novick, Diego, et al.
Publicado: (2012)

Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2011)

Treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, exploratory comparisons
por: Ascher-Svanum, Haya, et al.
Publicado: (2012)

A comparison of olanzapine and risperidone on the risk of psychiatric hospitalization in the naturalistic treatment of patients with schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2004)

Within‐drug benefit‐risk evaluation of olanzapine long‐acting injection at one and two years of treatment
por: Detke, Holland C., et al.
Publicado: (2014)

Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder: a 6-year, multinational, single-arm, open-label study
por: McDonnell, David P., et al.
Publicado: (2014)

A pooled analysis of injection site-related adverse events in patients with schizophrenia treated with olanzapine long-acting injection
por: Atkins, Susan, et al.
Publicado: (2014)

Maintenance of response with atypical antipsychotics in the treatment of schizophrenia: a post-hoc analysis of 5 double-blind, randomized clinical trials
por: Stauffer, Virginia, et al.
Publicado: (2009)

Empirically driven definitions of “good,” “moderate,” and “poor” levels of functioning in the treatment of schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2012)

Pharmacokinetics of olanzapine long-acting injection: the clinical perspective
por: Heres, Stephan, et al.
Publicado: (2014)

Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases
por: Detke, Holland C, et al.
Publicado: (2010)

Orally disintegrating olanzapine review: effectiveness, patient preference, adherence, and other properties
por: Montgomery, William, et al.
Publicado: (2012)

Change in level of productivity in the treatment of schizophrenia with olanzapine or other antipsychotics
por: Liu-Seifert, Hong, et al.
Publicado: (2011)

Predictors of continuation with olanzapine during the 1-year naturalistic treatment of patients with schizophrenia in Japan
por: Ye, Wenyu, et al.
Publicado: (2011)

Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism
por: McDonnell, David P, et al.
Publicado: (2010)

Predictors of antipsychotic monotherapy with olanzapine during a 1-year naturalistic study of schizophrenia patients in Japan
por: Ye, Wenyu, et al.
Publicado: (2012)

Baseline characteristics and hospitalizations in patients with schizophrenia receiving olanzapine long-acting injection: an interim analysis from a non-interventional, prospective observational safety study
por: Jones, Meghan E., et al.
Publicado: (2015)

One-year outcomes in schizophrenia after switching from typical antipsychotics to olanzapine in Japan: an observational study
por: Ye, Wenyu, et al.
Publicado: (2012)

Treatment of Schizophrenia With Long-Acting Fluphenazine, Haloperidol, or Risperidone
por: Olfson, Mark, et al.
Publicado: (2007)

Efficacy of olanzapine long-acting injection in patients with acutely exacerbated schizophrenia: an insight from effect size comparison with historical oral data
por: Detke, Holland C, et al.
Publicado: (2012)

Antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: a health care database analysis
por: Ye, Wenyu, et al.
Publicado: (2012)

Clinical outcomes with olanzapine long-acting injection: impact of the 3-hour observation period on patient satisfaction and well-being
por: Anand, Ernie, et al.
Publicado: (2016)

Reasons for continuing or discontinuing olanzapine in the treatment of schizophrenia from the perspectives of patients and clinicians
por: Chen, Jian, et al.
Publicado: (2011)

A 6-year open-label study of the efficacy and safety of olanzapine long-acting injection in patients with schizophrenia: a post hoc analysis based on the European label recommendation
por: Anand, Ernie, et al.
Publicado: (2015)

Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States
por: Furiak, Nicolas M, et al.
Publicado: (2009)

Dose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia
por: Hill, Angela L, et al.
Publicado: (2011)

Olanzapine long-acting injection: a review of first experiences of post-injection delirium/sedation syndrome in routine clinical practice
por: Bushe, Chris J, et al.
Publicado: (2015)

Clinical consequences of switching from olanzapine to risperidone and vice versa in outpatients with schizophrenia: 36-month results from the worldwide schizophrenia outpatients health outcomes (W-SOHO) study
por: Hong, Jihyung, et al.
Publicado: (2012)

Switching to olanzapine long-acting injection from either oral olanzapine or any other antipsychotic: comparative post hoc analyses
por: Ciudad, Antonio, et al.
Publicado: (2013)

Reduction in Multiple Cardiometabolic Risk Factors With Combined Olanzapine/Samidorphan Compared With Olanzapine: Post Hoc Analyses From a 24-Week Phase 3 Study
por: Correll, Christoph U, et al.
Publicado: (2022)

Does participation in a weight control program also improve clinical and functional outcomes for Chinese patients with schizophrenia treated with olanzapine?
por: Montgomery, William, et al.
Publicado: (2014)

Early Glycemic Response Predicts Achievement of Subsequent Treatment Targets in the Treatment of Type 2 Diabetes: A Post hoc Analysis
por: Fu, Haoda, et al.
Publicado: (2015)

Erratum to: Early Glycemic Response Predicts Achievement of Subsequent Treatment Targets in the Treatment of Type 2 Diabetes: A Post hoc Analysis
por: Fu, Haoda, et al.
Publicado: (2015)

The relationship, structure and profiles of schizophrenia measurements: a post-hoc analysis of the baseline measures from a randomized clinical trial
por: Chen, Lei, et al.
Publicado: (2011)

Long-term healthcare costs and functional outcomes associated with lack of remission in schizophrenia: a post-hoc analysis of a prospective observational study
por: Haynes, Virginia S, et al.
Publicado: (2012)

Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia
por: Di Lorenzo, Rosaria, et al.
Publicado: (2010)

Comparison of clinical outcomes with orodispersible versus standard oral olanzapine tablets in nonadherent patients with schizophrenia or bipolar disorder
por: Novick, Diego, et al.
Publicado: (2017)

Quality of life in children and adolescents with bipolar I depression treated with olanzapine/fluoxetine combination
por: Walker, Daniel J., et al.
Publicado: (2017)

The longitudinal interplay between negative and positive symptom trajectories in patients under antipsychotic treatment: a post hoc analysis of data from a randomized, 1-year pragmatic trial
por: Chen, Lei, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_tco4uhtjpd3qgh47id9ufviuqu